← ANALYST RATINGS · TIPRANKS
Damora Therapeutics (DMRA): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $46.67, the highest $60.00, the lowest $40.00. The average is +153.1% from the last price of $18.44.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $18.00 → $18.50+2.8% | Hold | +0.3% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $18.50 → $19.00+2.7% | Hold | +3.0% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $18.00 → $18.50+2.8% | Hold | +0.3% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $17.50 → $18.00+2.9% | Hold | −2.4% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $18.50 → $19.00+2.7% | Hold | +3.0% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $17.50 → $18.00+2.9% | Hold | −2.4% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $40.00 | Buy | +116.9% | Reiterated | 29.09.26on TipRanks 10:15 | −0.2%next day +3.2% · 5 days −7.3% | ↗ |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | $40.00 → $60.00+50.0% | Buy | +225.4% | Reiterated | 24.09.26on TipRanks Sep 25 08:31 | −0.7%next day +1.4% · 5 days +0.2% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $45.00 | Buy | +144.0% | Reiterated | 18.09.26on TipRanks 16:35 | −0.4%next day −1.9% · 5 days −8.2% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $50.00 | Buy | +171.1% | Reiterated | 11.08.26on TipRanks 10:55 | +3.1%next day +1.9% · 5 days +5.1% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $45.00 | Buy | +144.0% | Reiterated | 11.08.26on TipRanks 06:25 | +3.1%next day +1.9% · 5 days +5.1% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $40.00 | Buy | +116.9% | Reiterated | 10.08.26on TipRanks Aug 11 06:45 | −1.2%next day +3.1% · 5 days +5.3% | ↗ |
| Marc Frahm★★★★★★★★★★#223 · hits 56% · avg +25.8% | TD Cowen | — | Buy | — | Reiterated | 10.08.26on TipRanks Aug 11 02:45 | −1.2%next day +3.1% · 5 days +5.3% | ↗ |
| Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% | Leerink Partners | $55.00 → $51.00−7.3% | Buy | +176.6% | Reiterated | 15.05.26on TipRanks 11:20 | +4.2%next day +1.3% · 5 days +2.0% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $46.00 | Buy | +149.5% | Initiated | 25.03.26on TipRanks 09:25 | +4.2%next day +4.1% · 5 days +0.4% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $45.00 | Buy | +144.0% | Initiated | 17.02.26on TipRanks Mar 11 17:10 | +2.6%next day +1.5% · 5 days +5.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Damora Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $46.67 at a price of $21.28 (+119.3%); now: $46.67 at $18.44 (+153.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 12 | 11 | 9 | 6 | 5 |
| Buy | 1 | 3 | 5 | 11 | 9 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 30.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.48 (from $-0.60 to $-0.37). Last quarter: $-0.39.
Best top-analyst consensus in the sector · Healthcare
About Damora Therapeutics
- CEO: Jennifer A. Jarrett
- Employees: 7
- Building 23, Waltham, MA, 02453, US
- www.damoratx.com
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Data from the stock’s TipRanks forecast page, read 119 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗